株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ブドウ膜悪性黒色腫:パイプライン製品の分析

Uveal Melanoma - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 302507
出版日 ページ情報 英文 155 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.77円で換算しております。
Back to Top
ブドウ膜悪性黒色腫:パイプライン製品の分析 Uveal Melanoma - Pipeline Review, H2 2017
出版日: 2017年10月10日 ページ情報: 英文 155 Pages
概要

ブドウ膜悪性黒色腫は、最もよく見られる眼球内腫瘍で、癌(悪性)細胞がブドウ膜と呼ばれる眼球部分に見られる疾患です。ブドウ膜には、メラニンを形成する細胞(メラノサイト)が含まれています。このメラニン細胞が癌化すると、メラノーマと呼ばれます。症状には、虹彩上の暗斑、緑内障、眼痛、眼の赤みなどが含まれます。

当レポートでは、ブドウ膜悪性黒色腫に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

ブドウ膜悪性黒色腫の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

ブドウ膜悪性黒色腫:企業で開発中の治療薬

ブドウ膜悪性黒色腫:大学/機関で研究中の治療薬

ブドウ膜悪性黒色腫:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

ブドウ膜悪性黒色腫:企業で開発中の製品

ブドウ膜悪性黒色腫:大学/機関で研究中の製品

ブドウ膜悪性黒色腫の治療薬開発に従事している企業

  • Aura Biosciences, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Celldex Therapeutics, Inc.
  • Cleveland BioLabs, Inc.
  • Eli Lilly and Company
  • Immunocore Limited
  • Navigen Pharmaceuticals, Inc.
  • Novartis AG
  • PEP-Therapy SAS
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.

ブドウ膜悪性黒色腫:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

ブドウ膜悪性黒色腫:最近のパイプライン動向

ブドウ膜悪性黒色腫:休止中のプロジェクト

ブドウ膜悪性黒色腫:開発が中止された製品

ブドウ膜悪性黒色腫:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9747IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma - Pipeline Review, H2 2017, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.

Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveal Melanoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 9, 8, 1 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.

Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Uveal Melanoma - Overview
    • Uveal Melanoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Uveal Melanoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Uveal Melanoma - Companies Involved in Therapeutics Development
    • Aeglea BioTherapeutics Inc
    • Bellicum Pharmaceuticals Inc
    • Bristol-Myers Squibb Co
    • Celldex Therapeutics Inc
    • Cleveland BioLabs Inc
    • Delcath Systems Inc
    • Eli Lilly and Co
    • Iconic Therapeutics Inc
    • Immunocore Ltd
    • Iovance Biotherapeutics Inc
    • Navigen Inc
    • Novartis AG
    • PEP-Therapy SAS
    • Pfizer Inc
    • Polaris Pharmaceuticals Inc
    • Spectrum Pharmaceuticals Inc
    • Syndax Pharmaceuticals Inc
    • Tesaro Inc
  • Uveal Melanoma - Drug Profiles
    • AEB-1102 - Drug Profile
    • AU-011 - Drug Profile
    • BPX-701 - Drug Profile
    • Cellular Immunotherapy for Metastatic Uveal Melanoma - Drug Profile
    • Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile
    • crizotinib - Drug Profile
    • emibetuzumab - Drug Profile
    • entinostat - Drug Profile
    • entolimod - Drug Profile
    • glembatumumab vedotin - Drug Profile
    • hI-con1 - Drug Profile
    • HPH-196 - Drug Profile
    • HPH-211 - Drug Profile
    • IMCgp-100 - Drug Profile
    • ipilimumab + nivolumab - Drug Profile
    • KCN-1 - Drug Profile
    • LXS-196 - Drug Profile
    • melphalan - Drug Profile
    • merestinib - Drug Profile
    • NAV-2729 - Drug Profile
    • niraparib - Drug Profile
    • nutlin-3 - Drug Profile
    • pasireotide ER - Drug Profile
    • pegargiminase - Drug Profile
    • PEP-010 - Drug Profile
    • sotrastaurin acetate - Drug Profile
    • sunitinib malate - Drug Profile
    • Vaccine for Oncology - Drug Profile
    • vincristine sulfate - Drug Profile
  • Uveal Melanoma - Dormant Projects
  • Uveal Melanoma - Discontinued Products
  • Uveal Melanoma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Uveal Melanoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Uveal Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H2 2017
  • Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
  • Uveal Melanoma - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2017
  • Uveal Melanoma - Pipeline by Cleveland BioLabs Inc, H2 2017
  • Uveal Melanoma - Pipeline by Delcath Systems Inc, H2 2017
  • Uveal Melanoma - Pipeline by Eli Lilly and Co, H2 2017
  • Uveal Melanoma - Pipeline by Iconic Therapeutics Inc, H2 2017
  • Uveal Melanoma - Pipeline by Immunocore Ltd, H2 2017
  • Uveal Melanoma - Pipeline by Iovance Biotherapeutics Inc, H2 2017
  • Uveal Melanoma - Pipeline by Navigen Inc, H2 2017
  • Uveal Melanoma - Pipeline by Novartis AG, H2 2017
  • Uveal Melanoma - Pipeline by PEP-Therapy SAS, H2 2017
  • Uveal Melanoma - Pipeline by Pfizer Inc, H2 2017
  • Uveal Melanoma - Pipeline by Polaris Pharmaceuticals Inc, H2 2017
  • Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
  • Uveal Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2017
  • Uveal Melanoma - Pipeline by Tesaro Inc, H2 2017
  • Uveal Melanoma - Dormant Projects, H2 2017
  • Uveal Melanoma - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Uveal Melanoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top